Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Bristol Myers Squibb
Bristol Myers Squibb
Top 40 Best-Selling Oncology Drugs in 2023 by 2022 Data
Xtalks
Mon, 02/5/24 - 10:17 am
oncology
cancer
Keytruda
Revlimid
Opdivo
Imbruvica
Darzalex
Merck
Bristol Myers Squibb
AbbVie
Janssen
FDA sets date for high-profile CAR-T adcomm for Bristol's Abecma, J&J's Carvykti
Fierce Pharma
Sun, 02/4/24 - 12:39 pm
Bristol Myers Squibb
Abecma
FRDA
CAR-T
JNJ
Carvykti
Bristol Myers CEO sees mid-decade transition, late decade growth
Reuters
Sun, 02/4/24 - 12:35 pm
Bristol Myers Squibb
Pharma CEOs
Chris Boerner
BMS more likely to bet on bolt-ons after recent buying spree
Fierce Biotech
Fri, 02/2/24 - 11:59 am
Bristol Myers Squibb
M&A
earnings
Cour gets $105M, pharma help to ‘reprogram’ autoimmune disease
BioPharma Dive
Tue, 01/30/24 - 11:10 am
Cour Pharmaceuticals
funding
autoimmune disease
Roche
Pfizer
Bristol Myers Squibb
nanoparticles
BMS' subcutaneous Opdivo clears first phase 3 trial
Pharmaphorum
Mon, 01/29/24 - 11:06 am
Bristol Myers Squibb
Opdivo
clinical trials
kidney cancer
subcutaneous Opdivo
BMS won out against other pharmas in bid for RayzeBio, just days after competing for Karuna
Fierce Biotech
Thu, 01/25/24 - 09:02 pm
Bristol Myers Squibb
M&A
Rayze Bio
radiopharmaceuticals
Karuna, Cerevel might be just the start of psychiatry drug M&A
BioPharma Dive
Tue, 01/23/24 - 11:17 am
M&A
Karuna Therapeutics
Cerevel Therapeutics
schizophrenia
AbbVie
Bristol Myers Squibb
Two more pharmas practice their Accent, invest in $75M series C round
Fierce Biotech
Tue, 01/23/24 - 10:47 am
Accent Therapeutics
funding
RNA
Bristol Myers Squibb
JNJ
AbbVie
Another big pharma competed for Karuna, submitting all-cash offer day before BMS deal announcement
Fierce Biotech
Mon, 01/22/24 - 10:17 pm
Karuna Therapeutics
Bristol Myers Squibb
M&A
Bristol Myers shows power of Opdivo-Yervoy combo in first-line colorectal cancer subset
Fierce Pharma
Sun, 01/21/24 - 05:09 pm
Bristol Myers Squibb
colorectal cancer
Opdivo-Yervoy
Jilted by Bristol Myers, Ikena cuts headcount by 35% in retreat from drug discovery
Fierce Biotech
Fri, 01/19/24 - 09:28 am
Ikena Oncology
Bristol Myers Squibb
layoffs
JPM24: Bristol Myers Squibb CEO Boerner emphasizes organic pipeline over recent M&A deals
Fierce Pharma
Tue, 01/9/24 - 10:49 am
Bristol Myers Squibb
Pharma CEOs
Christopher Boerner
JPMHC 2024
Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference
Reuters
Fri, 01/5/24 - 11:25 am
M&A
JPMHC 2024
AbbVie
AstraZeneca
Bristol Myers Squibb
Carmot Therapeutics
Eli Lilly
Biopharma Closes 2023 with Flurry of M&A Activity from AstraZeneca, BMS, Roche
BioSpace
Tue, 01/2/24 - 11:26 am
M&A
AstraZeneca
Gracell Biotechnologies
Bristol Myers Squibb
Rayze Bio
Roche
BMS enters radiopharma race with $4.1B acquisition of RayzeBio just 3 months after biotech went public
Fierce Biotech
Wed, 12/27/23 - 11:15 pm
Bristol Myers Squibb
RayzeBio
radiopharmaceuticals
M&A
Bristol Myers to acquire brain drug developer Karuna for $14B
BioPharma Dive
Fri, 12/22/23 - 09:44 am
Bristol Myers Squibb
Karuna Therapeutics
schizophrenia
M&A
KarXT
Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree
BioPharma Dive
Tue, 12/12/23 - 09:58 am
Bristol Myers Squibb
SystImmune
antibody-drug conjugate
cancer
ASH: Abecma’s survival data show why FDA wanted expert meeting on the Bristol Myers cell therapy
Fierce Pharma
Mon, 12/11/23 - 10:55 pm
ASH 2023
Abecma
FDA
CAR-T
Bristol Myers Squibb
Bristol Myers Squibb bids farewell to dealmaking czar Elizabeth Mily
Fierce Pharma
Sun, 12/10/23 - 11:03 pm
Bristol Myers Squibb
M&A
Elizabeth Mily
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »